Results from Mendelian randomization studies suggest that blood Apn concentrations are unlikely to be causally associated with metabolic disease, including type 2 diabetes [53], coronary artery disease [54], and obesity-related cancer [55]. This evidence concerns the gene ANPEP and obesity disorder.